These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 17031283)

  • 61. Radiation therapy for neovascular age-related macular degeneration revisited.
    Kim IK; Gragoudas ES
    Br J Ophthalmol; 2009 Mar; 93(3):279-80. PubMed ID: 19244026
    [No Abstract]   [Full Text] [Related]  

  • 62. Bevacizumab: a compassionate way of doing business?
    Spratt A; Ogunbowale L; Franks W
    Eye (Lond); 2007 Jun; 21(6):890-1; author reply 891. PubMed ID: 17363924
    [No Abstract]   [Full Text] [Related]  

  • 63. Bevacizumab: a new hope?
    Madhusudhana KC; Newsom RS
    Eye (Lond); 2009 Sep; 23(9):1755-7. PubMed ID: 19741717
    [No Abstract]   [Full Text] [Related]  

  • 64. Comparative effectiveness.
    Brown G
    Curr Opin Ophthalmol; 2008 May; 19(3):175-6. PubMed ID: 18408489
    [No Abstract]   [Full Text] [Related]  

  • 65. Retinal pigment epithelial tears and the management of exudative age-related macular degeneration.
    Barkmeier AJ; Carvounis PE
    Semin Ophthalmol; 2011 May; 26(3):94-103. PubMed ID: 21609221
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Editorial: update on the modern management of wet age-related macular degeneration.
    Devenyi RG
    Can J Ophthalmol; 2006 Apr; 41(2):133-8. PubMed ID: 16767199
    [No Abstract]   [Full Text] [Related]  

  • 67. Anti-VEGF for neovascular ARMD: visual improvement as the goal of therapy?
    Bopp S
    Br J Ophthalmol; 2007 Oct; 91(10):1259-60. PubMed ID: 17895411
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Therapeutic anti-VEGF antibodies.
    Lien S; Lowman HB
    Handb Exp Pharmacol; 2008; (181):131-50. PubMed ID: 18071944
    [TBL] [Abstract][Full Text] [Related]  

  • 69. I've heard that new medications to treat wet age-related macular degeneration (AMD) are available. Are these new medications better than current treatments?
    Johns Hopkins Med Lett Health After 50; 2006 Dec; 18(10):8. PubMed ID: 17290531
    [No Abstract]   [Full Text] [Related]  

  • 70. Should avastin be used to treat age-related macular degeneration in the NHS?--No.
    Chong NV
    Eye (Lond); 2009 Jun; 23(6):1250-3. PubMed ID: 19407836
    [No Abstract]   [Full Text] [Related]  

  • 71. Anti-vascular endothelial growth factor strategies for the treatment of choroidal neovascularization from age-related macular degeneration.
    Barouch FC; Miller JW
    Int Ophthalmol Clin; 2004; 44(3):23-32. PubMed ID: 15211174
    [No Abstract]   [Full Text] [Related]  

  • 72. CATT: Into the eye of a tiger.
    Sears J; Bena J; Singh AD
    Br J Ophthalmol; 2011 Jun; 95(6):761. PubMed ID: 21602481
    [No Abstract]   [Full Text] [Related]  

  • 73. Should Avastin be used to treat age-related macular degeneration in the NHS?--Yes.
    Raftery J; Dent L
    Eye (Lond); 2009 Jun; 23(6):1247-9. PubMed ID: 19407834
    [No Abstract]   [Full Text] [Related]  

  • 74. Incorrect citation.
    Bates DO
    Invest Ophthalmol Vis Sci; 2011 Jun; 52(7):4368; author response 4368. PubMed ID: 21693617
    [No Abstract]   [Full Text] [Related]  

  • 75. Shall we use Avastin or Lucentis for ocular neovascularization?
    Algvere PV; Kvanta A; Seregard S
    Acta Ophthalmol; 2008 Jun; 86(4):352-5. PubMed ID: 18498548
    [No Abstract]   [Full Text] [Related]  

  • 76. Vascular endothelial growth factor biology: clinical implications for ocular treatments.
    Bhisitkul RB
    Br J Ophthalmol; 2006 Dec; 90(12):1542-7. PubMed ID: 17114590
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Anecortave acetate.
    Clarke MS
    Ophthalmology; 2004 Dec; 111(12):2316; author reply 2316-7. PubMed ID: 15582099
    [No Abstract]   [Full Text] [Related]  

  • 78. [Avastin is not the same as Lucentis, and Lucentis is not the same as Avastin].
    Asensio-Sánchez VM
    Arch Soc Esp Oftalmol; 2009 Sep; 84(9):427. PubMed ID: 19809922
    [No Abstract]   [Full Text] [Related]  

  • 79. A review of drug options in age-related macular degeneration therapy and potential new agents.
    Yeoh J; Sims J; Guymer RH
    Expert Opin Pharmacother; 2006 Dec; 7(17):2355-68. PubMed ID: 17109611
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Preclinical efficacy of anecortave acetate.
    Clark AF
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S41-8. PubMed ID: 17240256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.